Publications by authors named "Anya Jiang"
Article Synopsis
- A study investigated real-world outcomes of neoadjuvant chemoimmunotherapy in patients with stage II-III non-small-cell lung cancer (NSCLC) in the U.S., focusing on treatment patterns and survival rates.
- It included 221 patients treated with neoadjuvant therapies, primarily platinum-based chemotherapy, with median event-free survival (EFS) at 17.6 months and overall survival (OS) at 48.5 months.
- Results showed that a significant 71% of patients experienced disease recurrence during follow-up, emphasizing the need for more effective treatment options to improve long-term survival.
Article Synopsis
- - The study investigates the relationship between event-free survival (EFS) and overall survival (OS) in patients with resected stage II to III non-small cell lung cancer (NSCLC) who received neoadjuvant therapy, highlighting the increased importance of EFS as a clinical end point in trials.
- - By analyzing data from 221 patients, the research finds a strong positive correlation between EFS and OS, revealing that patients who experience disease recurrence have significantly shorter OS, a higher risk of death, and greater healthcare costs related to their condition.
- - The results emphasize the potential of event-free survival as a reliable predictor of overall survival and underscore the necessity for developing new treatment options to address disease recurrence in these patients
Article Synopsis
- Spinal muscular atrophy (SMA) is a serious genetic disorder leading to muscle weakness, respiratory issues, and increased mortality, and this study focuses on the real-world health care costs and utilization for patients treated with disease-modifying therapies in the U.S.
- The analysis involved 74 patients under 2 years old who were treated with either nusinersen, onasemnogene abeparvovec, or both, comparing their health care resource usage and costs over more than a year after starting treatment.
- Findings showed that those treated with nusinersen had significantly higher rates of hospital visits and medical costs, while onasemnogene abeparvovec led to much higher pharmacy costs, indicating different economic impacts of these treatments
Article Synopsis
- Intermediate endpoints like disease-free survival (DFS) correlate well with overall survival (OS) in early-stage non-small cell lung cancer (NSCLC), but there's a lack of real-world data on the burden of recurrence.
- A study analyzed data from the Surveillance, Epidemiology, and End Results-Medicare database, focusing on patients with resected early-stage NSCLC to understand how real-world DFS relates to OS and the healthcare costs associated with disease recurrence.
- Results showed that patients who experienced recurrence had significantly shorter OS and incurred higher healthcare costs compared to those without recurrence, reinforcing the importance of maintaining disease-free status post-surgery.
Background: As the non-small cell lung cancer (NSCLC) adjuvant treatment landscape evolves, an evaluation of treatment patterns and outcomes of patients with early-stage, resected NSCLC eligible for adjuvant treatment in routine clinical practice is needed to better understand the unmet needs in this patient population.
Materials And Methods: Data from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database (2007-2019) were used to identify patients with newly diagnosed stage IB (tumor size ≥4cm)-IIIA (AJCC 7th edition) NSCLC who received primary surgery (index date). We assessed adjuvant treatment patterns, real-world disease-free survival (rwDFS; time from index date to first recurrence or death) and overall survival (OS; time from index date to death), and loco-regional recurrence pattern and treatment distribution.